Compare INOD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | ORKA |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1993 | N/A |
| Metric | INOD | ORKA |
|---|---|---|
| Price | $65.01 | $26.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $91.67 | $48.20 |
| AVG Volume (30 Days) | ★ 953.9K | 713.6K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.46 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $238,467,000.00 | N/A |
| Revenue This Year | $48.85 | N/A |
| Revenue Next Year | $25.93 | N/A |
| P/E Ratio | $61.42 | ★ N/A |
| Revenue Growth | ★ 73.57 | N/A |
| 52 Week Low | $26.41 | $5.49 |
| 52 Week High | $93.85 | $32.64 |
| Indicator | INOD | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 66.52 | 38.76 |
| Support Level | $50.90 | $25.23 |
| Resistance Level | $55.18 | $32.64 |
| Average True Range (ATR) | 3.05 | 2.19 |
| MACD | 1.65 | -0.59 |
| Stochastic Oscillator | 97.97 | 18.76 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.